Treatment of HIV / AIDS comprises antiretroviral drugs and lifestyle management ... Abacavir in the dose of 300 MG tablet is given two times a day. Associated side effects can be abdominal ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Viraday that needs to be taken just once a day for effective treatment. The three anti-HIV drugs efavirenz 600 mg, tenofovir 300 mg and emtricitabine 200mg comprise the drug Viraday. Viraday ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

The rate of vertical transmission of HIV ... treatment decisions. [12] Risks and benefits must be weighed and discussed with the patient before any treatment is initiated. Since zidovudine is the ...

What to avoid with this at-home COVID-19 treatment Paxlovid is a combination antiviral medication that contains nirmatrelvir (a protease inhibitor) and ritonavir (originally used to treat HIV ...

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...

The 21-year-old biotech company has just 130 employees, no revenue and no approved drugs. But in the past ... and arimoclomol is the first approved treatment for it. Genomics: Synthetic genomics ...

Under US law, compounding pharmacies can make and sell patent-protected drugs that are on the FDA's shortages list in limited ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

in combination with an optimized background regimen in people with multi-drug resistant HIV. HIV prevention data will include an analysis of newly initiated pre-exposure prophylaxis (PrEP ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...